Home

Scott Akamine

CIK 1816720 · Chief Legal Officer · last filed 2026-04-20

Scott Akamine is a Chief Legal Officer who has filed 11 SEC Form 4 insider transactions across 3 companies since 2021. The most recent filing, for KLRA, was dated Apr 20, 2026. Across all open-market trades the lifetime net is −$1.4M, making them a net seller over the disclosed history.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$0

Companies

3

Total Filings

11

Lifetime Open-Market Net

-$1.37M

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
KLRA Chief Legal Officer — $16.74 — $0 1 2026-04-20
Cerevel Therapeutics Holdings, Inc. (CERE) Delisted Chief Legal Officer 7,237 $44.96 $325.4K -$1.37M 6 2024-01-23
Cerevel Therapeutics Holdings, Inc. (CEREW) Delisted Chief Legal Officer — $18.07 — $0 1 2021-06-03

Recent Filings

11 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2026-04-20 KLRA Grant (A) — $0 EDGAR
2024-08-05 — Disp (D) −7,527 $0
2024-01-23 Cerevel Therapeutics Holdings, Inc. (CERE) Delisted Grant (A) — $0 EDGAR
2023-12-21 Cerevel Therapeutics Holdings, Inc. (CERE) Delisted Mixed +6,724 -$292.9K EDGAR
2023-12-07 — Notice (144) −10,000 -$413.7K EDGAR
2023-12-07 Cerevel Therapeutics Holdings, Inc. (CERE) Delisted Mixed — -$445.7K EDGAR
2023-12-05 — Notice (144) −7,500 -$262.5K EDGAR
2023-02-08 Cerevel Therapeutics Holdings, Inc. (CERE) Delisted Grant (A) — $0 EDGAR
2022-08-09 Cerevel Therapeutics Holdings, Inc. (CERE) Delisted Mixed — -$268.3K EDGAR
2022-02-11 Cerevel Therapeutics Holdings, Inc. (CERE) Delisted Grant (A) — $0 EDGAR
Showing 1–10 of 11
Page 1 of 2
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.